Marine Staurosporine Analogues: Activity and Target Identification in Triple-Negative Breast Cancer

被引：1

作者：

Chen, Ru-Yi ^{[1
]}

Ding, Li-Jian ^{[2
]}

Liu, Yan-Jun ^{[1
]}

Shi, Jin-Jin ^{[1
]}

Yu, Jing ^{[1
]}

Li, Chang-Yun ^{[1
]}

Lu, Jian-Fei ^{[1
]}

Yang, Guan-Jun ^{[1
]}

Chen, Jiong ^{[1
]}

机构：

[1] Ningbo Univ, Sch Marine Sci, State Key Lab Managing Biot & Chem Threats Qual &, Ningbo 315211, Peoples R China

[2] Ningbo Univ, Hlth Sci Ctr, Sch Pharm, Ningbo 315211, Peoples R China

来源：

MARINE DRUGS | 2024年 / 22卷 / 10期

关键词：

staurosporine analogue; apoptosis; triple-negative breast cancer; cancer stem cells; cell migration; STEM-CELLS; RHODIUM(III) COMPLEX; INDOLE ALKALOIDS; NATURAL-PRODUCTS; KINASE; PROMOTES; APOPTOSIS; SNAIL; PATHOGENESIS; INHIBITION;

D O I：

10.3390/md22100459

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Triple-negative breast cancer (TNBC) is a subtype of breast cancer with high mortality and drug resistance and no targeted drug available at present. Compound 4, a staurosporine alkaloid derived from Streptomyces sp. NBU3142 in a marine sponge, exhibits potent anti-TNBC activity. This research investigated its impact on MDA-MB-231 cells and their drug-resistant variants. The findings highlighted that compound 4 inhibits breast cancer cell migration, induces apoptosis, arrests the cell cycle, and promotes cellular senescence in both regular and paclitaxel-resistant MDA-MB-231 cells. Additionally, this study identified mitogen-activated protein kinase kinase kinase 11 (MAP3K11) as a target of compound 4, implicating its role in breast tumorigenesis by affecting cell proliferation, migration, and cell cycle progression.

引用

页数：18

共 50 条

[21] Triple-negative breast cancer
Chacon, Reinaldo D.
Costanzo, Maria V.
BREAST CANCER RESEARCH, 2010, 12
[22] Triple-negative breast cancer
Stockmans, Gert
Deraedt, Karen
Wildiers, Hans
Moerman, Philippe
Paridaens, Robert
CURRENT OPINION IN ONCOLOGY, 2008, 20 (06) : 614 - 620
[23] Triple-Negative Breast Cancer
Foulkes, William D.
Smith, Ian E.
Reis-Filho, Jorge S.
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (20): : 1938 - 1948
[24] Triple-negative breast cancer
Bartsch R.
Ziebermayr R.
Zielinski C.C.
Steger G.G.
Wiener Medizinische Wochenschrift, 2010, 160 (7-8) : 174 - 181
[25] Triple-Negative Breast Cancer
Liedtke, Cornelia
Schmutzler, Rita
Schneeweiss, Andreas
Loibl, Sybille
Thill, Marc
Heitz, Florian
BREAST CARE, 2010, 5 (05) : 359 - 363
[26] Triple-negative breast cancer
Aschenbrenner, Diane S.
AMERICAN JOURNAL OF NURSING, 2020, 120 (08) : 22 - 23
[27] Triple-negative breast cancer
Reinaldo D Chacón
María V Costanzo
Breast Cancer Research, 12
[28] Identification of Target Genes Related to Sulfasalazine in Triple-Negative Breast Cancer Through Network Pharmacology
Yu, Haochen
Hu, Ke
Zhang, Tao
Ren, Haoyu
MEDICAL SCIENCE MONITOR, 2020, 26
[29] cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
Gaule, Patricia B.
Crown, John
O'Donovan, Norma
Duffy, Michael J.
EXPERT OPINION ON THERAPEUTIC TARGETS, 2014, 18 (09) : 999 - 1009
[30] Identification of Cancer-Specific Glycoproteins in Triple-Negative Breast Cancer
Tseng, L. H.
Argani, P.
Li, Y.
Tian, Y.
Lopez, M. F.
Sarracino, D.
Rezai, T.
Athanas, M.
Krastins, B.
Chan, D. W.
Zhang, H.
MODERN PATHOLOGY, 2009, 22 : 72A - 72A

← 1 2 3 4 5 →